Elevation Oncology
Biotechnology, 888 7th Ave Fl 12, Boston, Massachusetts, 10106, United States, 11-50 Employees
Who is ELEVATION ONCOLOGY
Elevation Oncology is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significa...
Read More
-
Headquarters: 888 7th Ave Fl 12, Boston, Massachusetts, 10106, United States
-
Date Founded: 2019
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
-
CEO:
Joseph Ferra
Email
Phone
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 325414 |
Show More
Does something look wrong? Fix it. | View contact records from ELEVATION ONCOLOGY
Elevation Oncology Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Elevation Oncology
Answer: Elevation Oncology's headquarters are located at 888 7th Ave Fl 12, Boston, Massachusetts, 10106, United States
Answer: Elevation Oncology's official website is https://elevationoncology.com
Answer: Elevation Oncology's revenue is $1 Million to $5 Million
Answer: Elevation Oncology's SIC: 2836
Answer: Elevation Oncology's NAICS: 325414
Answer: Elevation Oncology has 11-50 employees
Answer: Elevation Oncology is in Biotechnology
Answer: Elevation Oncology contact info: Phone number: Website: https://elevationoncology.com
Answer: Elevation Oncology is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. We are rethinking drug development by seeking out innovative, selective cancer therapies that can be matched to a patients unique tumor characteristics. Our lead candidate, EO-3021, is a potential best-in-class antibody drug conjugate (ADC) designed to target Claudin 18.2, a clinically validated molecular target. EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. We are working to rapidly advance EO-3021 into the clinic in the US across a range of solid tumor indications, as well as exploring other opportunities through new or existing partnerships and business development opportunities to expand our novel oncology pipeline.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Powered by
Sign in to CIENCE GO Data to uncover contact details
Free credits every month